Fonds de solidarité FTQ
Fonds de solidarité FTQ is a private equity and venture capital firm based in Montreal, Canada, with additional offices in Quebec. Established in 1983, the firm specializes in investing in small and medium-sized businesses across various sectors, including natural resources, aerospace, agri-food, life sciences, and culture. It primarily focuses on projects that require funding of $3 million or more and provides loans up to $2 million. The firm actively seeks investment opportunities in Quebec, particularly in regions such as Abitibi-Témiscamingue and Montérégie. Fonds de solidarité FTQ invests in a range of activities, including business succession, financial restructuring, and market development, while avoiding sectors like retail, real estate, and biotechnology. It typically engages in equity financing and unsecured debt with investment horizons ranging from five to ten years. The firm aims to support projects that positively impact the Quebec economy and often takes either minority or majority stakes in its portfolio companies.
Top Sectors
https://crunchbase.com/organization/***
https://linkedin.com/company/***
Past deals in Nova Scotia
IMV
Post in 2020
IMV Inc., headquartered in Dartmouth, Canada, is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies and vaccines against infectious diseases. Founded in 2000, the company utilizes its proprietary delivery platform (DPX) to directly program immune cells within the body, enhancing their ability to target and eliminate specific threats. IMV's lead drug candidate, DPX-Survivac, is a targeted T cell therapy that has shown promising results in late-stage ovarian cancer and relapsed/refractory DLBCL, with multiple Phase 2 clinical trials ongoing across six cancer indications. Additionally, the company is developing a DPX-based vaccine candidate against COVID-19 and DPX-RSV, targeting the respiratory syncytial virus strain A. IMV collaborates with infectious disease experts and has partnerships in the animal health sector, including an agreement with Pfizer Animal Health.
IMV
Post in 2020
IMV Inc., headquartered in Dartmouth, Canada, is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies and vaccines against infectious diseases. Founded in 2000, the company utilizes its proprietary delivery platform (DPX) to directly program immune cells within the body, enhancing their ability to target and eliminate specific threats. IMV's lead drug candidate, DPX-Survivac, is a targeted T cell therapy that has shown promising results in late-stage ovarian cancer and relapsed/refractory DLBCL, with multiple Phase 2 clinical trials ongoing across six cancer indications. Additionally, the company is developing a DPX-based vaccine candidate against COVID-19 and DPX-RSV, targeting the respiratory syncytial virus strain A. IMV collaborates with infectious disease experts and has partnerships in the animal health sector, including an agreement with Pfizer Animal Health.
IMV
Post in 2019
IMV Inc., headquartered in Dartmouth, Canada, is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies and vaccines against infectious diseases. Founded in 2000, the company utilizes its proprietary delivery platform (DPX) to directly program immune cells within the body, enhancing their ability to target and eliminate specific threats. IMV's lead drug candidate, DPX-Survivac, is a targeted T cell therapy that has shown promising results in late-stage ovarian cancer and relapsed/refractory DLBCL, with multiple Phase 2 clinical trials ongoing across six cancer indications. Additionally, the company is developing a DPX-based vaccine candidate against COVID-19 and DPX-RSV, targeting the respiratory syncytial virus strain A. IMV collaborates with infectious disease experts and has partnerships in the animal health sector, including an agreement with Pfizer Animal Health.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.